Neuropeptide Y has been shown to modulate mammalian circadian rhythms (Soscia and Harrington 2005) and there has been interest in its potential for anti-obesity drug development (Yulyaningsih et al. 2011) due to increased expression exerting anorexigenic effects (Yi et al. 2018). Here, NPY is linked to obesity due to melanocortin 4 receptor deficiency.